Karyopharm Therapeutics, Inc.

March 24, 2026 -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has entered into a securities purchase agreement with RA Capital Management for a private placement that is expected to result in gross proceeds of approximately $30 million before deducting placement agent fees and offering expenses, and an additional approximately $44 million of gross proceeds if the accompanying warrants are exercised in full. In the private placement, the Company agreed to sell 1,030,354 shares of common stock at a price of $6.785 per share, 3,391,164 pre-funded warrants at a price of $6.7849 per pre-funded warrant, and accompanying warrants to purchase 4,421,518 shares of common stock with an exercise price of $10.00 per share. The pre-funded warrants will have an exercise price of $0.0001 per share of common stock, will be immediately exercisable and will not expire. The accompanying warrants will be immediately exercisable and will expire 30 days following the public announcement by the Company of topline results from the Phase 3 XPORT-EC-042 clinical trial of selinexor in patients with endometrial cancer. The private placement is expected to close on or about March 26, 2026, subject to the satisfaction of customary closing conditions. The private placement was priced at-the-market under Nasdaq rules. The Company expects that the net proceeds of the private placement, together with its existing liquidity, including cash, cash equivalents and investments, as well as cash flow from net product revenue and license and other revenue, will enable it to fund its current operating plans into late Q3 2026. The Company intends to use the proceeds from the private placement for general corporate purposes, including to support the Company's ongoing and planned clinical trial activities. Jefferies and Piper Sandler acted as placement agents for the private placement. The offer and sale of the shares of common stock, pre-funded warrants, warrants, or any other securities (including the shares of common stock issuable upon exercise of the pre-funded warrants and warrants) are not being registered under the Securities Act of 1933, as amended (the "Securities Act"), or any state securities laws. The shares of common stock, pre-funded warrants, warrants, or any other securities (including the shares of common stock issuable upon exercise of the pre-funded warrants and warrants) may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and any applicable state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy shares of common stock, pre-funded warrants, warrants, or any other securities, nor shall there be any offer, solicitation or sale of shares of common stock, pre-funded warrants, warrants, or any other securities (including the shares of common stock issuable upon exercise of the pre-funded warrants and warrants) in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful. Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in 50 ex-U.S. territories and countries, including the European Union, the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). The content above comes from the network. if any infringement, please contact us to modify.

iStock, beast01 Missing one of its co-primary endpoints could make it difficult for Karyopharm Therapeutics to score conventional approval for Xpovio in myelofibrosis, according to Jefferies analysts. Karyopharm Therapeutics’ push to expand its multiple myeloma drug Xpovio into myelofibrosis has hit a speedbump. Tuesday, the biotech unveiled mixed results in a Phase 3 myelofibrosis study, with an investigational Xpovio regimen meeting just one of two primary endpoints. Following the readout, the company’s shares dropped to $5.44 apiece at market close, an 18.3% decrease from its previous closing price. Karyopharm nevertheless intends to engage with the FDA to discuss “the totality of the data” and see how that might shape up to a regulatory path forward for Xpovio in this indication, according to a Tuesday release . Jefferies, however, isn’t optimistic: “We see low chance of conventional FDA approval w/ current dataset,” analysts told investors in a note sent the same day. Xpovio is an oral nuclear export inhibitor that was approved in 2019 in combination with dexamethasone for patients with relapsed or refractory multiple myeloma who have undergone at least four prior lines of therapy. Last year, the drug made $114.9 million . Karyopharm forecasts net U.S. product revenue to be between $115 million to $130 million this year. In the Phase 3 SENTRY study , Karyopharm combined Xpovio with ruxolitinib, a JAK inhibitor that is marketed by Incyte under brand names such as Jakafi and Opzelura. The trial enrolled more than 350 patients with myelofibrosis and who had never been treated with JAK inhibitors. Comparators were given placebo plus ruxolitinib. At 24 weeks, 50% of patients treated with the Xpovio combo achieved at least a 35% decrease in spleen volume, a key disease marker. At the same time point, 28% of comparators on ruxolitinib alone hit this endpoint, resulting in a statistically significant advantage for the Xpovio regimen. Xpovio was able to sustain this benefit over time, with 47% of patients maintaining a 35% spleen volume reduction by 36 weeks, versus 23% in controls. However, the Xpovio regimen failed to hit SENTRY’s other co-primary endpoint of symptom improvement, as measured by a change in the absolute total symptom score. Patients treated with Karopharm’s combo saw a 9.89-point improvement in the scale, versus 10.86 points in those who received ruxolitinib alone. A key opinion leader consulted by RBC Capital Markets “did not seem as concerned about the trial not hitting on its symptom scale endpoint,” the firm told investors in a Tuesday note. The expert, RBC continued, pointed out that ruxolitinib’s symptomatic benefits “are so robust that . . . it may not be possible for any drug to hit on this endpoint.” What interested the expert more were the survival signals that Karyopharm reported. The biotech touted “promising” overall survival (OS) outcomes in its Tuesday release, with the Xpovio- ruxolitinib combo reducing the risk of death from any cause by 57% versus controls. A posthoc analysis also showed that the spleen volume response could be predictive of overall survival. While RBC’s key opinion leader has expressed “some caution” about whether this survival signal is real, he nevertheless “believes this would be a very meaningful finding if it plays out longer-term,” the firm said. A significant survival benefit, analysts added, would trump the symptom score miss. Karyopharm intends to present its OS data to the FDA in building its case for Xpovio’s expansion into myelofibrosis, the biotech said on Tuesday, though it did not yet provide a specific timeline for when such a filing could occur.

Karyopharm has seen sales stagnate for Xpovio. But the Massachusetts company hopes that mixed results can pave the way to FDA approval in a new indication for the nuclear transport modulator. After gaining approval to treat multiple myeloma and generating sales of $120 million in its third full year on the market, Karyopharm’s Xpovio has stagnated in the clinic and in the market.On Tuesday, the Massachusetts company provided results from a phase 3 trial that it hopes can help the nuclear transport modulator regain some of its momentum. But investors aren’t sharing in the company’s enthusiasm, with shares falling sharply after the readout and a separate financial development at the company.Testing Xpovio (selinexor) in combination with Incyte and Novartis’ blockbuster Jakafi (ruxolitinib) in patients with first-line myelofibrosis (MF), the study met one of its two primary endpoints, with the combo demonstrating a statistically significant improvement in spleen volume reduction of 35% or more (SVR35) compared to Jakafi and placebo.The experimental combo produced spleen responses in 50% of patients, compared to a 28% figure for the control arm, Karyopharm said in a press release.The trial did not achieve its co-primary endpoint, however, it came up short on patient-reported symptom scores after 24 weeks compared to baseline. As measured by the Absolute Total System Score (Abb-TSS), patients on the combo reported a 9.9-point improvement, compared to a 10.9 improvement for those on Jakafi and placebo.On a Tuesday morning conference call, Karyopharm CEO Richard Paulson called the data an “important milestone” for the company and “an encouraging step forward” for patients who have MF.“These results suggest the potential to improve on key dimensions of treatment benefit in a disease where patients and physicians continue to need better options,” Paulson said, adding that the company plans to meet with the FDA to discuss the data and a potential submission for approval in the indication. Naturally, Karyopharm focused on the spleen volume aspect of the trial, in which the combo produced rapid and sustained results. After 12 weeks, 49% of patients on the combo achieved SVR35 compared to 20% in the control arm. The durability of the combo was demonstrated at week 36 by 47% of patients achieving the standard compared to 23% of those on Jakafi and placebo.Additionally, the company said the trial results indicated a positive overall survival signal for the combo. Karyopharm added that post-hoc analyses at weeks 12 and 24 suggest SVR35 “may predict overall survival.” The company will continue to monitor patients in the trial to evaluate overall survival.“The early, the sustained, the substantial proportion of patients that achieved that SVR really demonstrates that meaningful benefit, layered on top of the promising overall survival signal and a manageable safety and tolerability profile really suggest a positive benefit,” Reshma Rangwala, M.D., Ph.D., Karyopharm’s chief medical officer, said during the call. “We look forward to engaging with the FDA on the totality of that data.”Separately on Tuesday, Karyopharm revealed a new financing arrangement with RA Capital Management, under which it will generate $30 million in proceeds from the sale of 1.03 million shares of its common stock for $6.79 each. This likely played some role in the company’s share movement Tuesday.Karyopharm has struggled in recent years, with its share price declining more than 95% over the last 5 years. After the twin news releases Tuesday, shares were down some 17%. After gaining three FDA nods in a span of 17 months for Xpovio, the FDA rejected an expansion bid for the drug to be used as a maintenance therapy in endometrial cancer. In each of the last four years, annual sales have been stagnant, toggling between $112 million and $120 million.In 2023, the company executed a round of layoffs, reducing its headcount by 20%. Last year came another 20% reduction. It opened this year with 228 employees, down from 442 at the start of 2022.